Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema

AIM: To observe the efficacy of aflibercept and ranibizumab in the treatment of diabetic macular edema(DME).METHODS: Patients with DME who visited the ophthalmology department of Xingtai People's Hospital for the first time from November 2019 to February 2020 were included in the study. They we...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Xiu-Xian Wang, Pei-Cheng Zhang, Jing Xie, Xiang-Rong Zuo
Formato:	article
Lenguaje:	EN
Publicado:	Press of International Journal of Ophthalmology (IJO PRESS) 2021
Materias:	diabetic macular edema aflibercept ranibizumab intravitreal injection effect Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/aa28b6b9770a40eb851da109dcc786dd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aa28b6b9770a40eb851da109dcc786dd
record_format	dspace
spelling	oai:doaj.org-article:aa28b6b9770a40eb851da109dcc786dd2021-11-22T14:22:33ZEfficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema1672-512310.3980/j.issn.1672-5123.2021.12.32https://doaj.org/article/aa28b6b9770a40eb851da109dcc786dd2021-12-01T00:00:00Zhttp://ies.ijo.cn/cn_publish/2021/12/202112032.pdfhttps://doaj.org/toc/1672-5123AIM: To observe the efficacy of aflibercept and ranibizumab in the treatment of diabetic macular edema(DME).METHODS: Patients with DME who visited the ophthalmology department of Xingtai People's Hospital for the first time from November 2019 to February 2020 were included in the study. They were randomly divided into the aflibercept group and the ranibizumab group. 3+PRN(pro re nata)was used, and the interval time between two injections was at least 4wk. All patients were given three injections first. During follow-up, the patient's best corrected visual acuity(BCVA)and central foveal thickness(CFT)were used to determine whether to inject again. All patients were followed-up for 12mo. The changes of BCVA, CFT, intraocular pressure and injection times were recorded in two groups before and after treatment.RESULTS: During preoperative and postoperative follow-up, there were statistical differences in LogMAR BCVA and CFT of the two groups respectively(P<0.05). The comparison between the two groups showed no statistical significance during the BCVA and the CFT follow-up(P>0.05). At the end of follow-up, there was a statistical difference in the number of injections between the two groups(t= -6.403, P<0.05). The average number of injections was 6.094±0.689 in the aflibercept group and 7.231±0.652 in the ranibizumab group. No ocular complications or systemic adverse reactions occurred in all patients.CONCLUSION: Compared with intravitreal injection of ranibizumab and aflibercept for the treatment of DME can achieve similar treatment effect, but the number of injections is less in the aflibercept.Xiu-Xian WangPei-Cheng ZhangJing XieXiang-Rong ZuoPress of International Journal of Ophthalmology (IJO PRESS)articlediabetic macular edemaafliberceptranibizumabintravitreal injectioneffectOphthalmologyRE1-994ENGuoji Yanke Zazhi, Vol 21, Iss 12, Pp 2183-2186 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	diabetic macular edema aflibercept ranibizumab intravitreal injection effect Ophthalmology RE1-994
spellingShingle	diabetic macular edema aflibercept ranibizumab intravitreal injection effect Ophthalmology RE1-994 Xiu-Xian Wang Pei-Cheng Zhang Jing Xie Xiang-Rong Zuo Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
description	AIM: To observe the efficacy of aflibercept and ranibizumab in the treatment of diabetic macular edema(DME).METHODS: Patients with DME who visited the ophthalmology department of Xingtai People's Hospital for the first time from November 2019 to February 2020 were included in the study. They were randomly divided into the aflibercept group and the ranibizumab group. 3+PRN(pro re nata)was used, and the interval time between two injections was at least 4wk. All patients were given three injections first. During follow-up, the patient's best corrected visual acuity(BCVA)and central foveal thickness(CFT)were used to determine whether to inject again. All patients were followed-up for 12mo. The changes of BCVA, CFT, intraocular pressure and injection times were recorded in two groups before and after treatment.RESULTS: During preoperative and postoperative follow-up, there were statistical differences in LogMAR BCVA and CFT of the two groups respectively(P<0.05). The comparison between the two groups showed no statistical significance during the BCVA and the CFT follow-up(P>0.05). At the end of follow-up, there was a statistical difference in the number of injections between the two groups(t= -6.403, P<0.05). The average number of injections was 6.094±0.689 in the aflibercept group and 7.231±0.652 in the ranibizumab group. No ocular complications or systemic adverse reactions occurred in all patients.CONCLUSION: Compared with intravitreal injection of ranibizumab and aflibercept for the treatment of DME can achieve similar treatment effect, but the number of injections is less in the aflibercept.
format	article
author	Xiu-Xian Wang Pei-Cheng Zhang Jing Xie Xiang-Rong Zuo
author_facet	Xiu-Xian Wang Pei-Cheng Zhang Jing Xie Xiang-Rong Zuo
author_sort	Xiu-Xian Wang
title	Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
title_short	Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
title_full	Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
title_fullStr	Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
title_full_unstemmed	Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
title_sort	efficacy of aflibercept versus ranibizumab in the treatment of diabetic macular edema
publisher	Press of International Journal of Ophthalmology (IJO PRESS)
publishDate	2021
url	https://doaj.org/article/aa28b6b9770a40eb851da109dcc786dd
work_keys_str_mv	AT xiuxianwang efficacyofafliberceptversusranibizumabinthetreatmentofdiabeticmacularedema AT peichengzhang efficacyofafliberceptversusranibizumabinthetreatmentofdiabeticmacularedema AT jingxie efficacyofafliberceptversusranibizumabinthetreatmentofdiabeticmacularedema AT xiangrongzuo efficacyofafliberceptversusranibizumabinthetreatmentofdiabeticmacularedema
_version_	1718417572224827392

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema

Ejemplares similares